CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The AfriCoLeish project focuses on developing safe and effective oral treatments for visceral leishmaniasis (VL) in East Africa, particularly for patients co-infected with HIV. It aims to improve current treatment options and management strategies through clinical studies assessing new drug combinations.
Visceral leishmaniasis (VL) is fatal if left untreated;
East Africa is one of the key endemic areas in the world.
Untreated patients are part of the retransmission cycle and VL-HIV co-infection is an additional emerging problem.Existing VL monotherapies are difficult to administer, toxic, costly and long with emerging resistance.
Sodium stibogluconate and paromomycin (SSG&PM) has been developed as the first combination treatment for VL in East Africa and it is currently recommended as first line…
DRUGS FOR NEGLECTED DISEASES INITIATIVE FONDATION
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Belgium, ANTWERPEN
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
United Kingdom, London
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Sudan, Khartoum
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
